Navigation Links
Avastin under trial to test efficacy for pancreatic tumours!

Northwestern Memorial Hospital along with Northwestern University Feinberg School of Medicine is conducting a Phase II clinical trial to determine if avastin is effective in pancreatic tumours.//

The drug also known as bevacizumab is an anti-angiogenesis drug that is designed to inhibit the growth of blood vessels in tumours.

The test is being done to see that it in combination with abdominal radiation therapy and chemotherapy can reduce localized pancreatic tumours that have not metastasized or spread to other systems or organs in the body.

Northwestern Memorial is the sole clinical site where the research trial is being conducted.

"Our findings from the previous study suggest that the combination of chemotherapy and radiation is a safe and effective treatment method to reduce the local extent of pancreatic tumors," said Dr. Talamonti, MD, chief of the Division of Surgical Oncology at Northwestern Memorial Hospital, associate professor of surgery at Northwestern University Feinberg School of Medicine and co-investigator on the study

Another view was presented by William Small, Jr., MD, radiation oncologist, Northwestern Memorial Hospital, associate professor, Radiation Oncology, Northwestern University Feinberg School of Medicine and principal investigator for the trial, "The current study, which will be conducted over two years, will help us evaluate whether adding Avastin may also provide an effective combination to reduce the tumour and increase survival rates. Avastin is designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays an important role in tumour angiogenesis or blood vessel formation, and maintenance of existing tumour vessels. By inhibiting VEGF, Avastin is thought to interfere with the blood supply to tumours, a process that is critical to tumour growth and metastasis.”

As per statistics by the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death among adults in America. Approximately 1 out of 4 patients with pancreatic cancer will live at least one year after the cancer is found.

Therefore it is very important that clinical trials are conducted and new viable solutions are found for this problem.


'"/>




Related medicine news :

1. Avastin, anti-Cancer Drug leads to Blindness and Other Complications
2. Warning on Avastin Updated
3. FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy
4. Cancer Drug Avastin Fights Brain Tumors too
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. How do babies understand language?
7. Doctor samples come under the ambit of advertisement
8. Latest device for cardiac revival under test
9. Heart disease in women being under-treated
10. Safety of soy under suspicion
11. Education in women brings sounder sleep
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: